Le Lézard
Classified in: Health
Subjects: AWD, TDS, MAT

Boston IVF Showcases Pioneering Fertility Research at the 2023 ASRM Scientific Congress & Expo


Charting a Path to Tomorrow, Boston IVF's Groundbreaking Research in 2023 Continues to Shape the Future of Fertility Care

BOSTON, Oct. 19, 2023 /PRNewswire-PRWeb/ -- Boston IVF, a renowned leader in fertility research and patient care since its establishment in 1986, is proud to announce its substantial participation in the 2023 American Society for Reproductive Medicine (ASRM) Scientific Congress and Expo. This prestigious annual event, in New Orleans, Louisiana, from October 14-18, brought together global experts to share groundbreaking advancements in technology, treatments, and patient care in reproductive medicine.

"We take pride in the many distinguished Boston IVF experts who presented at this exciting exposition." ? David Stern, CEO of Boston IVF

Boston IVF's team of reproductive endocrinologists, scientists, clinicians, and researchers presented over 20 pioneering research studies, along with education symposia and roundtables. These presentations unveiled innovative results that will enhance the quality of fertility and family-building care for patients worldwide.

This year, four distinguished individuals from Boston IVF were recognized nationally by the ASRM for their exceptional contributions:

The roots of Boston IVF's prolific research program run deep, in collaboration with Harvard Medical School, the Beth Israel Deaconess Medical Center, and other prestigious clinical affiliates. Since its inception, Boston IVF has contributed more than 500 papers and abstracts to the field, many of which have translated into life-changing innovations for individuals seeking successful pregnancies and family-building opportunities.

In 2019, Boston IVF expanded its global impact through a partnership with the renowned, Spain-based Eugin Group, broadening the scope of research possibilities and initiatives.

Led by Boston IVF's Chief Scientific Officer, Denny Sakkas, PhD and Director of Clinical Research and board-certified reproductive endocrinologist, Denis Vaughan, MD, Boston IVF's in-house, full-time research program consists of over 50 experts, including reproductive endocrinologists, scientists, embryologists, clinicians, data analysts, and more. Together, they play a pivotal role in advancing the field of reproductive science and introducing new clinical protocols, surgical techniques, public policy analyses, and other valuable insights to their peers worldwide.

"Through our dedicated research department, we strive daily to unravel the mysteries of fertility, unlocking the potential for hope and fulfillment for countless individuals and couples," said Denis Vaughan, MD.

Denny Sakkas, PhD, also added, "Every discovery, every breakthrough, is a testament to our commitment to transforming dreams into reality."

For over three decades, Boston IVF's innovative research has yielded remarkable breakthroughs in fertility care, including several notable milestones:

David Stern, CEO of Boston IVF, expressed his enthusiasm for the 2023 ASRM Congress, noting, "We take pride in our many distinguished experts who presented at this exciting exposition. It reflects our ongoing commitment to advancing fertility treatment options and improving the lives of our patients. We are grateful for every opportunity to share our knowledge and collaborate with fellow experts in the field."

Highlighted Boston IVF Presenters and Topics at the 2023 ASRM Congress:

STAY CONNECTED WITH BOSTON IVF

Follow Boston IVF on Instagram

Follow Boston IVF on LinkedIn

Follow Boston IVF on Facebook

Follow Boston IVF on Twitter

ABOUT BOSTON IVF

Boston IVF is one of the largest and most experienced fertility networks in the United States, with more than 150,000 babies born since 1986. Founded as one of the nation's first private practice IVF centers, the Boston IVF network has grown to include over 30 reproductive endocrinologists across 30 centers throughout Massachusetts, Maine, New Hampshire, Rhode Island, New York, Delaware, Idaho, Indiana, North Carolina, Ohio, and Utah. A renowned innovator of reproductive technologies, advanced protocols, and cutting-edge research, Boston IVF has achieved numerous "firsts" in reproductive care. Its scientific and research arm continues to pave the way for breakthroughs in fertility care and its accredited REI Fellowship Program has graduated numerous reproductive endocrinologists as part of its mission to train the next generation of fertility experts.

Media Contact

Zoe Marzi, Boston IVF, 1 7814346515, [email protected], https://www.bostonivf.com/

Theo LoPreste, Boston IVF, 1 781-434-6451, [email protected], https://www.bostonivf.com/

Twitter

SOURCE Boston IVF


These press releases may also interest you

at 09:10
Turner Construction Company is pleased to announce that it has agreed to acquire 100 percent of Dornan Engineering Group, a specialist mechanical, electrical, instrumentation and commissioning engineering contractor with operations in Ireland, the...

at 09:10
Masimo will release second quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, August 6, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted...

at 09:10
Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company developing novel, non-opioid pain therapeutics, today announced publication of a multicenter, randomized clinical trial evaluating vocacapsaicin on the cover of the August 2024...

at 09:05
Eclipse Bioinnovations, Inc. (Eclipsebio), the leading RNA genomics company developing and commercializing novel, data-driven technologies and analyses that interrogate RNA, today announced the launch of its proprietary eMERGEtm platform. eMERGE is...

at 09:05
Dr. Vince Clinical Research (DVCR), a full-service contract research organization (CRO) specializing in early-phase clinical trials, is pleased to announce "Accelerating Clinical & Drug Development Timelines with AI," an exclusive webinar exploring...

at 09:04
Inimmune, a clinical stage biotech company focused on the development of novel immunotherapies, vaccines, and vaccine adjuvants announced today the dosing of the first patient in its Phase 1 single ascending dose study of INI-4001 in patients with...



News published on and distributed by: